Breaking News

Recipharm Signs Agreement with RedHill Biopharma

CDMO will manufacture RHB-105 for treatment of H. pylori infection

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Stockholm, Sweden-based Recipharm AB has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma Ltd. for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion.  Recipharm will be responsible for the supply of the remaining clinical trial material and ongoing future commercial supply. RHB-105 is...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters